SWOG 9713:CISPLATIN & ETOPOSIDE & CONCURRENT RADIOTHERAPY FOR SMALL C

SWOG 9713：顺铂

• 批准号: 6309583
• 负责人: ALAN MARSHALL MILLER
• 金额: $ 1.12万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6309583
• 关键词: antineoplastics; carboplatin; cis platinum compound; clinical research; combination cancer therapy; etoposide; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer radiation therapy; paclitaxel; small cell lung cancer

Small cell lung cancer accounts for 25% of all lung cancer diagnoses. One-third of those patients present with limited stage disease and are considered potentially curable with current therapy. Despite improved outcome with concurrent chemoradiotherapy, the majority of patients will develop progressive disease. Novel approaches are indicated. This study will evaluate the use of carboplatin and paclitaxel as consolidative therapy in the treatment of SCLS. The induction schema will be similar to that of SWOG 8991. Consolidation therapy will include Paclitaxel at a dose of 200 mg/m2 over three hours followed by carboplatin at an AUC of six. A two-drug induction regimen of cisplatin and etoposide will be utilized versus prior trials utilizing a vincristine-containing regimen. Radiotherapy will be increased to a total dose of 6,100 cGy. The study will utilize the previously established SWOG definition of limited disease which includes patients with malignant pleural effusions.

小细胞肺癌占所有肺癌诊断的25%。其中三分之一的患者表现为有限期疾病，并被认为可以用目前的治疗方法治愈。尽管同步放化疗改善了预后，但大多数患者将发展为进行性疾病。提出了新的方法。本研究将评估卡铂和紫杉醇作为SCLS的联合治疗。归纳模式将类似于SWOG 8991。巩固治疗将包括紫杉醇剂量200mg /m2超过3小时，随后卡铂AUC为6。将使用顺铂和依托泊苷的双药诱导方案与先前使用长春新碱的方案进行比较。放射治疗的总剂量将增加到6 100 gy。该研究将利用先前建立的SWOG对有限疾病的定义，包括恶性胸腔积液患者。